ArticleBioinformation2025
Disrupted circadian control promotes oncogenesis in breast cancer.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer progression is increasingly linked to disturbances in circadian rhythm genes, although the underlying molecular mechanisms remain poorly understood. Circadian rhythm genes help maintain normal biological processes and their disruption contributes to breast cancer development. Transcriptomic data from breast cancer (MCF-7) and normal breast (MCF-10A) cell lines from the GSE76370 dataset were analyzed using the limma R package to identify differentially expressed genes. Functional enrichment and network analyses using GO, KEGG, STRING and Cytoscape revealed 1,788 DEGs, including 1,008 upregulated genes involved in DNA replication, chromatin remodeling and PI3K-Akt signaling and 780 downregulated genes associated with cell adhesion and apoptosis. Disrupted expression of core circadian genes (BMAL1, CLOCK and PER3) and hub genes such as ACTB, GAPDH and CDK1 suggests that circadian gene dysregulation promotes breast cancer progression and represents a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.